Sirius Medicine, LLC

Kevin N Morris

Michael D Weil

Rainer M Malzbender

Targeting agents are provided that have an affinity for aberrant cells and tissues. These agents are comprised of chelates, ligands, and/or particles combined with high atomic weight elements so that treatment with ionizing electromagnetic radiation (X-rays, or Gamma rays) results in a higher dose to aberrant cells and tissues than other cells and tissues of a host. The invention further provide methods to enhance the tumor to normal tissue damage ratio by concentrating agents with high atomic number elements to the site of the tumor prior to administering radiotherapy. The result is greater therapeutic efficacy with fewer side effects. These compounds also permit diagnostic uses in combination with the therapeutic use.

Targeting agents for enhancing radiation therapy

Contrast agents developed specifically for x-ray diagnostics provide dose-enhanced radiotherapy and radiosurgery. The presence of heavy elements, for example, gold or iron, from these contrast agents, even small quantities, leads to a major dose increase in target tissue when combined with in vivo calibration of the amount of contrast agent. The technique can also be used in combination with other techniques, such as focused x-rays, to achieve further enhancement of therapeutic ratio. The technique is enhanced by employing oil-based contrast agents, which will remain in the target much longer than conventional agents. Through optimization of the equipment it is possible to achieve very large ratios of dose in target to dose in healthy tissue.

Growing community of inventors

Denver, CO, United States of America

Kevin N Morris